U.S. Pfizer is expanding its COVID boosters, opening up an additional dose for under-16s

U.S. Pfizer is expanding its COVID boosters, opening up an additional dose for under-16s

U.S. health officials said Thursday that 16- and 17-year-olds should receive a booster dose of the COVID-19 vaccine produced by Pfizer six months after the last vaccination.

The U.S. and many other countries have already called for adults to take boosting drugs to boost immunity, which can decline a few months after vaccination, which has intensified with the discovery of a new omicron variant.

On Thursday, the Food and Drug Administration gave emergency permission to 16- and 17-year-olds to receive a third dose of a vaccine produced by Pfizer and his partner BioNTech. And a few hours later, the Centers for Disease Control and Prevention raised the final hurdle – saying that teens should get their strength when the time comes.

CDC director Rochelle Valensky told the Associated Press that amplifiers lose protection against infection over time and that “we are facing an option that requires more immunity to protect.”

Acting FDA Commissioner Dr. Janet Woodcock said in a statement: lib remains, “he said. .

The Pfizer vaccine is the only option in the U.S. for anyone under the age of 18 to use as a primary vaccine or booster. It is not yet clear when or when adolescents under the age of 16 may need a third dose of Pfizer.

Vaccinations for children under 5 started last month, using special low-dose Pfizer strokes. By this week, nearly 5 million children aged 5-11 had received their first dose.

The additional infectious delta variant causes almost all COVID-19 infections in the United States and much of the world. It is not yet clear how the vaccines will resist the new and significantly different omicron mutant. But there is strong evidence that amplifiers can help increase protection against delta-caused infections, which is currently the biggest threat.

Complicating the decision to extend the boosters to 16- and 17-year-olds is that a similar vaccine produced by Pfizer and Moderna has been associated with rare side effects. This type of heart inflammation, called myocarditis, is mainly seen in young men and adolescent boys.

The FDA notes that the increase in COVID-19 cases in the U.S. means that the benefits of amplifiers far outweigh the potential risk of rare side effects, especially since the coronavirus itself can cause severe inflammation of the heart.

Health officials who already help teenagers in Israel say side effects at the third dose are rare.

A study in the U.S. this week offered additional confidence. Researchers at pediatric hospitals across the country examined medical records and found that rare side effects are usually mild and that people recover quickly. The study was published in the journal Circulation on Monday.

.

This article is republished from – Voa News – Read the – original article.

Subscribe

Get the best of Newspaper delivered to your inbox daily

Most Viewed

Related Stories